Serenity Pharmaceuticals

11 articles about Serenity Pharmaceuticals

• Acerus Announces Amendment and Restatement of the Promissory Note Related to the Up-Front Fee Payable to Former Serenity Securityholders

  6/7/2022

  Acerus Pharmaceuticals Corporation (the “ Company ” or “ Acerus ”) (TSX:ASP; OTCQB:ASPCD) today announced that it has entered into an amended and restated promissory note (the “ A&R Note ”) covering the up-front fee owed to former Serenity Pharmaceuticals LLC (“ Serenity ”) securityholders.

• Acerus Announces Closing of Acquisition of Serenity Pharmaceuticals LLC and Acquisition of Global Rights to Noctiva™Conference Call to be Held on March 9, 2022 at 8:30am ET to Discuss Transaction

  3/7/2022

  Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) (TSX:ASP; OTCQB:ASPCF) today announced the closing of its previously-announced acquisition of Serenity Pharmaceuticals LLC (“Serenity”), including the global rights to its Noctiva™ brand.

• Avadel Pharma Enters Into Exclusive Negotiations With Serenity For Noctiva

  8/18/2017

• FDA Approves Serenity’s Noctiva (Desmopressin Acetate) – The First Drug Approved For The Treatment Of Nocturia

  3/7/2017

• Serenity Release: FDA Approves First Treatment For Frequent Urination At Night Due To Overproduction Of Urine

  3/3/2017

• FDA Panel Expresses Concerns Over Allergan-Serenity Drug for Nighttime Urination

  10/18/2016

• CPEX Pharmaceuticals' Partner Serenity Pharmaceuticals Announces Development and Commercialization Agreement with Allergan Inc. for Nocturia Product Candidate

  4/1/2010

• Allergan Inc. Licenses Drug for Night-Time Urination; To Pay Serenity Pharmaceuticals $43 Million Upfront; $122 Million in Future Payments

  4/1/2010

• CPEX Pharmaceuticals Announces Completion of Phase 2 Trial for Urology Drug by Serenity Pharmaceuticals

  2/26/2009

• CPEX Pharmaceuticals Announces Initiation of Phase II Trial for Urology Indication by Serenity Pharmaceuticals

  11/17/2008

• CPEX Pharmaceuticals and Serenity Pharmaceuticals Announce Collaboration on Drug Candidate for Urology Indication

  8/4/2008